Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs

Simple item page
dc.contributor.authorRathore, C.
dc.contributor.authorUpadhyay, N.
dc.contributor.authorKaundal, R.
dc.contributor.authorDwivedi, R. P.
dc.contributor.authorRahatekar, Sameer S.
dc.contributor.authorJohn, A.
dc.contributor.authorDua, K
dc.contributor.authorTambuwala, M. M.
dc.contributor.authorJain, S.
dc.contributor.authorChaudari, D.
dc.contributor.authorNegi, P.
dc.date.accessioned2020-04-29T10:10:41Z
dc.date.available2020-04-29T10:10:41Z
dc.date.issued2020-01-31
dc.description.abstractBackground: The poor biopharmaceutical properties of thymoquinone (TQ) obstruct its development as a hepatoprotective agent. To surmount the delivery challenges of TQ, phospholipid nanoconstructs (PNCs) were constructed. Method: PNCs were constructed employing microemulsification technique and systematic optimization by three-factor three level Box-Behnken design. Result: Optimized PNC composition exhibited nano size (<100 nm), spherical morphology, within acceptable range of polydispersity index (0.55), high drug entrapment efficiency (>90%), controlled drug release pattern, and neutral surface charge (zeta potential of −0.65 mV). After oral administration of a single dose of PNC, it showed a relative bioavailability of 386.03% vis-à-vis plain TQ suspension. Further, TQ-loaded PNC demonstrated significant enhanced hepato-protective effect vis-à-vis pure TQ suspension and silymarin, as evidenced by reduction in the ALP, ALT, AST, bilirubin, and albumin level and ratified by histopathological analysis. Conclusion: TQ-loaded PNCs can be efficient nano-platforms for the management of hepatic disorders and promising drug delivery systems to enhance oral bioavailability of this hydrophobic molecule.en_UK
dc.identifier.citationRathore C, Upadhyay N, Kaundal R, et al., (2020) Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs. Expert Opinion on Drug Delivery, Volume 17, Issue 2, 2020, pp. 237-253en_UK
dc.identifier.issn1742-5247
dc.identifier.urihttps://doi.org/10.1080/17425247.2020.1716728
dc.identifier.urihttps://dspace.lib.cranfield.ac.uk/handle/1826/15416
dc.language.isoenen_UK
dc.publisherTaylor and Francisen_UK
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectThymoquinoneen_UK
dc.subjectbox-Behnken designen_UK
dc.subjectlipid carriersen_UK
dc.subjectmicroemulsifcationen_UK
dc.subjecthepatotoxicityen_UK
dc.subjectpharmacokineticsen_UK
dc.titleEnhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructsen_UK
dc.typeArticleen_UK

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Enhanced_oral_bioavailability-2020.pdf
Size:
2.3 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Staff publications (SATM)